Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Horizon Therapeutics Public Limited Company | HZNP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
116.30 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 90.56 - 116.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 116.30 | USD |
Horizon Therapeutics Public Limited Company Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 26.63B | - | - | - | 52.34 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Horizon Therapeutics Pub... News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HZNP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 115.40 | 116.38 | 115.35 | 116.11 | 4,259,390 | 0.90 | 0.78% |
1 Year | 109.25 | 116.38 | 90.56 | 108.08 | 2,475,207 | 7.05 | 6.45% |
3 Years | 89.10 | 120.535 | 57.84 | 96.72 | 2,215,369 | 27.20 | 30.53% |
5 Years | 27.86 | 120.535 | 22.69 | 77.95 | 2,091,828 | 88.44 | 317.44% |
Horizon Therapeutics Pub... Description
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States. |